The Sage Group is at JPM/BIO Partnering in San Francisco from 13-16 January, 2025! Please click here to setup a meeting!

Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells

D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner

Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

The Sage Group: 30 Years of Successful Bioscience Transactions

Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)

Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan Diseases

Opportunity to License/Acquire CMX-2043 For Treatment of Traumatic Brain Injury

BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets